WEBULL
News
ENTX
1.250
+1.63%
0.020
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT) and Entera Bio (ENTX)
TipRanks · 2d ago
Entera Bio Submits Streamlined Phase 3 Plan for EB613
TipRanks · 3d ago
Entera Bio Submits Clinical Amendment To FDA Providing Streamlined Phase 3 Protocol, SAP, And Open-Label Extension Synopsis To IND 505(B)(2) Submission To Evaluate EB613; Entera Expects FDA Feedback Within 60 Days
Benzinga · 3d ago
Weekly Report: what happened at ENTX last week (0223-0227)?
Weekly Report · 5d ago
OPK Q4 net loss widens to USD 31.3 million from net income USD 14.0 million
Reuters · 02/26 21:14
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woman Osteoporosis Market (NASDAQ: ENTX)
TipRanks · 02/23 13:30
Weekly Report: what happened at ENTX last week (0216-0220)?
Weekly Report · 02/23 09:08
What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours
Benzinga · 02/19 06:49
Weekly Report: what happened at ENTX last week (0209-0213)?
Weekly Report · 02/16 09:08
Entera Bio Directors Go on a Buying Spree, Signaling Big Insider Confidence
TipRanks · 02/12 02:07
Entera Bio Shares Rise After Open Market Purchase By Board Members
NASDAQ · 02/11 15:38
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 02/09 17:05
Entera Bio Names Geno Germano Independent Board Chairman
TipRanks · 02/09 14:21
Entera Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 02/09 11:35
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Entera Bio (ENTX)
TipRanks · 02/09 11:30
Weekly Report: what happened at ENTX last week (0202-0206)?
Weekly Report · 02/09 09:08
Entera Bio Expands OPKO Partnership, Adds New Director
TipRanks · 02/04 13:42
Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet
TipRanks · 02/04 13:16
OPKO Health Expands Partnership With Entera Bio To Advance First-in-Class Oral Long Acting PTH Tablet
Benzinga · 02/04 13:05
More
Webull provides a variety of real-time ENTX stock news. You can receive the latest news about Entera Bio Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ENTX
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.